Andre Goy, M.D. provides perspective on CAR T-cell therapy for lymphoma: This is a game-changing therapy in a patient population that had few options, with only a small percentage able to undergo transplant if they respond to salvage therapy. The response rate is very high, greater than 80 percent. The response rate at three months seems like it is predictive of long-term outcomes, and one-third of patients in partial response converted to complete response over time, sometimes more than a year later. The complete response rate increased from 48 to 54 percent with longer follow-up, which is not a significant difference, but it is a substantial finding because it is not decreasing.